Your browser doesn't support javascript.
loading
Prevalence and Evolution of Noroviruses between 1966 and 2019, Implications for Vaccine Design.
Zhou, Hong-Lu; Chen, Li-Na; Wang, Song-Mei; Tan, Ming; Qiu, Chao; Qiu, Tian-Yi; Wang, Xuan-Yi.
Afiliação
  • Zhou HL; Key Laboratory of Medical Molecular Virology of MoE & MoH and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
  • Chen LN; Key Laboratory of Medical Molecular Virology of MoE & MoH and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
  • Wang SM; Laboratory of Molecular Biology, Training Center of Medical Experiments, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
  • Tan M; Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
  • Qiu C; College of Medicine, University of Cincinnati, Cincinnati, OH 45229, USA.
  • Qiu TY; Key Laboratory of Medical Molecular Virology of MoE & MoH and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
  • Wang XY; Zhong Shan Hospital, Shanghai Public Health Clinical Center, Shanghai Medical College, Fudan University, Shanghai 201508, China.
Pathogens ; 10(8)2021 Aug 11.
Article em En | MEDLINE | ID: mdl-34451477
Noroviruses (NoVs), a group of single-stranded RNA viruses causing epidemic acute gastroenteritis in humans, are highly diverse, consisting of multiple genogroups with >30 genotypes. Their continual evolutions make NoV vaccine design and development difficult. Here, we report a study of NoV sequences obtained from a population-based diarrhea surveillance in Zhengding County of Hebei Province spanning from 2001 to 2019 and those available in the GenBank database from 1966 to 2019. NoV genotypes and/or variants that may evade immunity were screened and identified based on primary and conformational structures for vaccine design. We selected 366, 301, 139, 74 and 495 complete VP1-coding nucleotide sequences representing the predominant genotypes of GII.4, GII.2, GII.3, GII.6 and GII.17, respectively. A total of 16 distinct GII.4 variants were identified, showing a typical linear evolutionary pattern of variant replacement, while only 1-4 variants of the other genotypes were found to co-circulate over the 40-50-year period without typical variant replacement. The vaccine strain GII.4c is close to variant Sydney_2012 (0.053) in their primary structure, but they are distinct at epitopes A and E in conformations. Our data suggested GII.4 variant Sydney_2012, GII.2 variant A, a GII.3 strain, GII.6 variants B and C and GII.17 variant D are primary candidate strains for NoV vaccine development.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prevalence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prevalence_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article